| Ident. | Authors (with country if any) | Title |
|---|
| 000644 |
Morvarid Karimi [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Robert R. Luedtke [États-Unis] ; Michelle Taylor [États-Unis] ; Robert H. Mach [États-Unis] ; Joel S. Perlmutter [États-Unis] | Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect? |
| 000A70 |
Marta G. Vuckovic [États-Unis] ; QUANZHENG LI [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise Elevates Dopamine D2 Receptor in a Mouse Model of Parkinson's Disease: In Vivo Imaging with [18F]Fallypride |
| 001805 |
Kjell Fuxe [Suède] ; Daniel Marcellino [Suède] ; Susanna Genedani [Italie] ; Luigi Agnati [Italie] | Adenosine A2A Receptors, Dopamine D2 Receptors and Their Interactions in Parkinson's Disease |
| 001853 |
Christoph Scherfler [Royaume-Uni] ; Naheed L. Khan [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Paola P. Piccini [Royaume-Uni] | Upregulation of dopamine D2 receptors in dopaminergic drugnaive patients with Parkin gene mutations |
| 001899 |
Matthias Reimold [Allemagne] ; Christoph Globas [Allemagne] ; Marc Gleichmann [Allemagne] ; Michael Schulze [Allemagne] ; Christian Gerloff [Allemagne] ; Roland Bares [Allemagne] ; H.-J. Machulla [Allemagne] ; Katrin Bürk [Allemagne] | Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome : Striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography |
| 001A86 |
Judith A. Strong [États-Unis] ; Arif Dalvi [États-Unis] ; Fredy J. Revilla [États-Unis] ; Alok Sahay [États-Unis] ; Frederick J. Samaha [États-Unis] ; Jeffrey A. Welge [États-Unis] ; JIANHUA GONG [États-Unis] ; Maureen Gartner [États-Unis] ; XIA YUE [États-Unis] ; LEI YU [États-Unis] | Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease |
| 001B37 |
Stefanie Klaffke [Allemagne] ; Andrea A. Kuhn [Allemagne] ; Michail Plotkin [Allemagne] ; Holger Amthauer [Allemagne] ; Daniel Harnack [Allemagne] ; Roland Felix [Allemagne] ; Andreas Kupsch [Allemagne] | Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration |
| 001C35 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 002119 |
Andrew H. Evans [Royaume-Uni] ; Durval C. Costa [Portugal] ; Sveto Gacinovic [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni] ; John D. O'Sullivan [Australie] ; Simon Heales [Royaume-Uni] ; Phillip Lee [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings |
| 002125 |
Valtteri Kaasinen [Finlande] ; Sargo Aalto [Finlande] ; Kjell Nagren [Finlande] ; Juha O. Rinne [Finlande] | Insular dopamine D2 receptors and Novelty seeking personality in Parkinson's disease |
| 002239 |
Sebastian Paus [Allemagne] ; Gert Seeger [Allemagne] ; Hans M. Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Mahha El-Faddagh [Allemagne] ; Markus M. Nöthen [Belgique] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease |
| 002317 |
Klaus L. Leenders [Pays-Bas] | Significance of non-presynaptic SPECT tracer methods in Parkinson's disease |
| 002325 |
Kirn R. Kessler [Allemagne] ; Gilbert Wunderlich [Allemagne] ; Harald Hefter [Allemagne] ; Rüdiger J. Seitz [Allemagne] | Secondary progressive chronic manganism associated with markedly decreased striatal D2 receptor density |
| 002343 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor |
| 002477 |
Prithiva Navan [Royaume-Uni] ; Leslie J. Findley [Royaume-Uni] ; Jim A. R. Jeffs [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] | Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest Tremor and UPDRS part III in Parkinson's disease |
| 002479 |
Carsten Buhmann [Allemagne] ; Alexandra Bussopulos [Allemagne] ; Matthias Oechsner [Allemagne] | Dopaminergic response in Parkinsonian phenotype of Machado-Joseph Disease |
| 002483 |
Eng-King Tan [Singapour] ; YANNI TAN [Singapour] ; Anthea Chai [Singapour] ; Christopher Tan [Singapour] ; HUI SHEN [Singapour] ; Sau-Ying Lum [Singapour] ; Stephanie M. C. Fook-Cheong [Singapour] ; Mei-Ling Teoh [Singapour] ; YUAN YIH [Singapour] ; Meng-Cheong Wong [Singapour] ; YI ZHAO [Singapour] | Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease |
| 002497 |
Ruediger Hilker [Allemagne] ; Juergen Voges [Allemagne] ; Mehran Ghaemi [Allemagne] ; Ralf Lehrke [Allemagne] ; Jobst Rudolf [Allemagne] ; Athanasios Koulousakis [Allemagne] ; Karl Herholz [Allemagne] ; Klaus Wienhard [Allemagne] ; Volker Sturm [Allemagne] ; Wolf-Dieter Heiss [Allemagne] | Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in Parkinsonian humans |
| 002589 |
Daniel Tarsy [États-Unis] ; Gerald Indorf [États-Unis] | Tardive tremor due to metoclopramide |
| 002605 |
Guy Arnold [Allemagne] ; Klaus Tatsch [Allemagne] ; Eduardo Kraft [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes Schwarz [Allemagne] | Steele-Richardson-Olszewski syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study |
| 002765 |
J. Carsten Moller [Allemagne] ; Karin Stiasny [Allemagne] ; Volker Hargutt [Allemagne] ; Werner Cassel [Allemagne] ; Heiko Tietze [Allemagne] ; J. Hermann Peter [Allemagne] ; H.-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Evaluation of sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep under dopaminergic medication: A pilot study |
| 002788 |
| Drugs to treat gastrointestinal motility problems |
| 002808 |
| DA agonists: ergot derivatives: Bromocriptine |
| 002809 |
| DA agonists: Non-Ergot derivatives: Ropinirole |
| 002810 |
| DA agonists: Non-Ergot derivatives: Pramipexole |
| 002822 |
Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada] | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP |
| 002880 |
Frithjof Tergau [Allemagne] ; Stephan Wischer [Allemagne] ; Christian Wolf [Allemagne] ; Walter Paulus [Allemagne] | Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine |
| 002884 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 002A60 |
Eleni C. Maratos [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ronald K. B. Pearce [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus) |
| 002B03 |
C. Ramaker [Pays-Bas] ; W. J. T. Van De Beek [Pays-Bas] ; M. J. J. Finken [Pays-Bas] ; B. J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications : A systematic review |
| 002B06 |
R. L. Oliveri [Italie] ; G. Annesi [Italie] ; M. Zappia [Italie] ; D. Civitelli [Italie] ; E. V. De Marco [Italie] ; A. A. Pasqua [Italie] ; F. Annesi [Italie] ; P. Spadafora [Italie] ; A. Gambardella [Italie] ; G. Nicoletti [Italie] ; D. Branca [Italie] ; M. Caracciolo [Italie] ; U. Aguglia [Italie] ; A. Quattrone [Italie] | The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease |
| 002B36 |
R. A. Hauser [États-Unis] ; L. Gauger [États-Unis] ; W. M. Anderson [États-Unis] ; T. A. Zesiewicz [États-Unis] | Pramipexole-induced somnolence and episodes of daytime sleep |
| 002B69 |
Robert A. Hauser [États-Unis] ; Mervat N. Wahba [États-Unis] ; Theresa A. Zesiewicz [États-Unis] ; W. Mcdowell Anderson [États-Unis] | Modafinil treatment of pramipexole-associated somnolence |
| 002C10 |
Sarah A. Treseder [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Endogenous dopaminergic tone and dopamine agonist action |
| 002C69 |
L. Grevle [Norvège] ; C. Güzey [Norvège] ; H. Hadidi [Norvège] ; R. Brennersted [Norvège] ; J. R. Idle [Norvège] ; J. Aasly [Norvège] | Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease |
| 002D27 |
W. Ondo [États-Unis] ; MD [États-Unis] | Ropinirole for restless legs syndrome |
| 002D60 |
L. E. Davis [États-Unis] ; J. C. Adair [États-Unis] | Parkinsonism from methanol poisoning : Benefit from treatment with anti-Parkinson drugs |
| 002E24 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 002F25 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 002F26 |
Olivier Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 002F74 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 003036 |
H. L. Ryoo [États-Unis] ; D. Pierrotti [États-Unis] ; J. N. Joyce [États-Unis] | Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease |
| 003044 |
R. K. B. Pearce [Royaume-Uni] ; T. Banerji ; P. Jenner ; C. D. Marsden | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset |
| 003080 |
M. Gassen [Allemagne] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003101 |
G. K. Wenning [Autriche] ; E. Donnemiller [Autriche] ; R. Granata [Autriche] ; G. Riccabona [Autriche] ; Werner Poewe [Autriche] | 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease |
| 003106 |
J. Schwarz [Allemagne] ; K. Tatsch [Allemagne] ; T. Gasser ; G. Arnold ; W. H. Oertel | [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy |
| 003203 |
A. Antonini [Suisse] ; J. Schwarz [Suisse] ; W. H. Oertel [Suisse] ; O. Pogarell [Suisse] ; K. L. Leenders [Suisse, Allemagne] | Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease : A study with positron emission tomography and [11C]raclopride |
| 003236 |
I. Soykan [États-Unis] ; I. Sarosiek [États-Unis] ; J. Shifflett [États-Unis] ; G. F. Wooten [États-Unis] ; R. W. Mccallum [États-Unis] | Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease |
| 003377 |
L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
| 003568 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003703 |
J. O. Rinne [Finlande] ; A. Laihinen [Finlande] ; U. K. Rinne [Finlande] ; K. Nagren ; J. Bergman ; U. Ruotsalainen | PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease |
| 003739 |
L. Schelosky [Allemagne] ; J. Hierholzer ; J. Wissel ; M. Cordes ; Werner Poewe [Autriche] | Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT |
| 003791 |
P. Montagna [Italie] ; A. S. Gabellini ; L. Monari ; E. Lugaresi | Parkinsonian syndrome after long-term treatment with clebopride |
| 003796 |
J. Schwarz [Allemagne] ; K. Tatsch ; T. Vogl ; C. M. Kirsch ; C. Trenkwalder ; G. Arnold ; T. Gasser ; W. H. Oertel | Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia |
| 003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 003921 |
L. G. Miller ; Joseph Jankovic [États-Unis] | Sulpiride-induced tardive dystonia |
| 003929 |
U. K. Rinne ; A. Laihinen ; J. O. Rinne ; K. Nagren ; J. Bergman ; U. Ruotsalainen | Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease |
| 003930 |
K. D. Sethi ; A. Hitri ; B. I. Diamond | Phenytoin potentiation of neuroleptic-induced dyskinesias |
| 003A14 |
R. F. Pfeiffer ; L. H. Herrera ; C. S. Glaeske ; R. E. Hofman | CQP A01-403 in Parkinson's disease: an open-label pilot study |
| 003A96 |
F. Grandas ; N. Quinn ; P. Critchley ; A. Rohan ; C. D. Marsden ; S. M. Stahl | Antiparkinsonian activity of a single oral dose of PHNO |
| 003B02 |
W. J. Weiner ; S. A. Factor ; J. Sanchez-Ramos ; J. Berger | A double-blind evaluation of ciladopa in Parkinson's disease |
